Cited by 281AI in cancer detectionArtificial Intelligence in Healthcare and EducationRadiomics and Machine Learning in Medical Imaging

Artificial intelligence in oncology: current applications and future perspectives

Open access
Luchini, Claudio, Pea, Antonio, Scarpa, Aldo·2022·British Journal of Cancer

Abstract

Artificial intelligence (AI) is concretely reshaping the landscape and horizons of oncology, opening new important opportunities for improving the management of cancer patients. Analysing the AI-based devices that have already obtained the official approval by the Federal Drug Administration (FDA), here we show that cancer diagnostics is the oncology-related area in which AI is already entered with the largest impact into clinical practice. Furthermore, breast, lung and prostate cancers represent the specific cancer types that now are experiencing more advantages from AI-based devices. The future perspectives of AI in oncology are discussed: the creation of multidisciplinary platforms, the comprehension of the importance of all neoplasms, including rare tumours and the continuous support for guaranteeing its growth represent in this time the most important challenges for finalising the 'AI-revolution' in oncology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-021-01633-1

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Luchini and colleagues summarized 71 FDA-cleared devices in oncology up to 2021 and found radiology accounted for 54.9% and pathology 19.7%.

    “For example, Luchini and colleagues (194) summarized 71 FDA-cleared devices in oncology (up to 2021) and found that radiology accounted for the majority of approved devices (54.9%), followed by pathology (19.7%).”
  • The same study found breast cancer was the most commonly cited cancer type (31%), most commonly associated with radiology, providing evidence of advancing maturity of AI in mammography.

    “The same study also found that breast cancer was the most commonly cited cancer type (31%), most commonly associated with radiology, providing further evidence of the advancing maturity of AI in mammography.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Luchini, C., Pea, A., & Scarpa, A.
Affiliations
University of Verona (IT)
Corresponding author
  • Luchini, Claudio
  • Scarpa, Aldo
Venue
British Journal of Cancer
Published
2021-11-26
Volume
126
Issue
1
Pages
4-9
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W3215393627
Cited by
281
References
14
Citations by year
2026: 56 · 2025: 83 · 2024: 71 · 2023: 43 · 2022: 28
FWCI
12.50
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Associazione Italiana per la Ricerca sul Cancro (12182)
  • Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona (203885/2017)
Topics
  • Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
Keywords
artificial intelligence in oncology, AI-based medical devices, cancer diagnosis, breast cancer, lung cancer, prostate cancer, rare tumor, clinical implementation of AI
MeSH terms
Artificial Intelligence, Forecasting, Humans, Medical Oncology, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review